Adidas/Puma Origin Story Movie In Works Produced By Andrew ...

Dogs attack puma

EXCLUSIVE: Fortitude International has acquired rights to the sibling rivalry story behind iconic sports brands Adidas and Puma. Nadine de Barros and Robert Ogden Barnums fortitude will finance the untitled adidas/puma Project which is currently in development and out to directors.

Andrew Garfield, Rupert Fowler and de Barros are producing with Fowler writing. Production is scheduled to begin in 2017.

Set against the backdrop of the rise of n**i Germany and through the 1936 Berlin Olympics and World War II the film depicts the true story of the Dassler brothers, Adolf and Rudolf, and the family divide that resulted in the emergence of two of the strongest sports brands in history.

Lore has it the pair started a small shoemaking business in Bavaria, focusing primarily on hand-sewn athletic footwear. But as their business took off, the brothers grew increasingly frustrated with each other and in the mid-1940s Rudolf set up a rival shop, while Adi remained in the initial plant and renamed the company Adidas. In 1948, Rudolf registered his new company, Puma..Fortitude International will handle international with CAA on domestic.

Fortitude currently has pics in post that include Paul Rudd/Steve Coogan-starrer Ideal Home; comedy The Brits Are Coming with Uma Thurman; Backstabbing For Beginners starring Ben Kingsley; and Drunk Parents with Alec Baldwin and Salma Hayek.

Source: http://deadline.com/2016/12/fortitude-adidas-puma-origin-story-andrew-garfield-producer-1201864553/

Continue Reading ..

Puma Cancer Drug Suffers "Approvability Risk" On Extreme Side Effect

Living With puma: Family Share Home With Pet pantera

Neratinib is suffering greater "approvability risk" after Puma Biotechnology (PBYI) said Wednesday it had to add a second anti-diarrheal to the breast cancer regimen, prodding shares to a three-week low Thursday.

RBC analyst Simos Simeonidissees regulators questioning neratinib"s toxicity profile. Neratinib is used to treatHER2-positive early- and late-stage breast cancer. Diarrhea is a common side effect. In a prior phase 3 trial, 95.4% of patients experienced some form of diarrhea.

On Wednesday, Puma unveiled the results of a phase 2 trial aiming to cut down on neratinib-related diarrheaby combining with anti-diarrheal drugsloperamide and budesonide. Of the 40 patients on the combo, 15% experienced grade 3 diarrhea or above.

That compares with 25%-29% of 135 loperamide-alone patients who suffered grade 3 or above diarrhea.The median number of episodes was one with a median of three days" duration. In combination patients, the median number of days was 2.5 for one episode.

Simeonidisnotes the loperamide-alone data was much worse vs. Puma"s year-earlier presentation at the San Antonio Breast Cancer Symposium. Then, 16% of patients suffered neratinib-related diarrhea while also taking loperamide.

"A comparison of the graphs from last year"s SABCS distribution of grade 1-4 diarrhea shows that grade 3 only occurred in the first month," he wrote in a report. "However, this year"s presentation shows that grade 3 events occur during the first four months of treatment."

IBD"S TAKE: Drug and biotech stocks tumbled Wednesday on President-elect Donald Trump"s pledge to curb spiraling drug prices. Get the full look on IBD"s Industry Themes.

Still, Simeonidis believes neratinib should garner U.S. Food and Drug Administration and European Medicines Agency approvals. Though he wonders whether regulators might hesitate on the drug"s toxicity.

"The recent second negative regulatory surprise for investors increases the approvability risk for neratinib in the form of, "What else could come up that we assumed we were OKwith?"" he wrote.

Credit Suisse analyst Kennen MacKay was more bullish on neratinib and called the results "encouraging." No patient discontinued neratinib use in the most recent trial as a result of diarrhea.

Neratinib alone increased progression-free survival (PFS) by three months with an objective response rate (ORR) of 33%. In combination with chemotherapyfulvestrant, PFS increased by 3.7 months and ORR hit 58%.

Simeonidiskept his sector perform rating on puma stock. mackay has an outperform rating and 111 price target on Puma stock. In early trading on the stock market today, Puma stock slipped as much as 9.4%, touching a three-week low. Midday, it was down 8%, near 36.50.

RELATED:

Source: http://www.investors.com/news/technology/puma-cancer-drug-suffers-approvability-risk-on-extreme-side-effect/

Continue Reading ..